SLC25A32 and gastric adenocarcinoma: The GEPIA2.0 database presents the differential expression of SLC25A32 in paired tumours and healthy tissues, validating the evidence that SLC25A32 was significantly upregulated in most tumours, including lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), oesophageal carcinoma (ESCA), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THTM) (Figure 1(a)).